Basking Biosciences Announces Publication Showing BB-031 Restores Blood Flow in a Microfluidic Model of Acute Ischemic Stroke (AIS)
RESEARCH TRIANGLE, N.C., July 30, 2026 /PRNewswire/ -- Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), today announced the publication of preclinical research...
RESEARCH TRIANGLE, N.C., July 30, 2026 /PRNewswire/ -- Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a first-in-class, targeted, reversible thrombolytic therapy for acute ischemic stroke (AIS), today announced the publication of preclinical research...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.